https://botanixpharma.com/wp-content/uploads/AdobeStock_226352071-scaled.jpeg 1707 2560 Haley Chartres /wp-content/uploads/botanix-logo.png Haley Chartres2021-02-12 21:24:042023-03-13 21:16:44Novartis’ Sandoz splurges on a trio of GSK antibiotics, doubling down with a $500M bet on a field struggling to combat resistant microbes
Novartis’ Sandoz splurges on a trio of GSK antibiotics, doubling down with a $500M bet on a field struggling to combat resistant microbes
Article extract | “Novartis’ acquisition represents a double-down on an antibiotics field facing an existential crisis from resistant “super bugs” that have sent most major drugmakers running for the hills — including Novartis, which dumped its antibiotic R&D program in 2018. But adding ever-greater volume to their generic antibiotics portfolio could offer Novartis some bottom-line value in the dwindling space.”
Click through to read the full article on Endpoints News.